The European Union is ready to help drug companies expand coronavirus vaccine production to clear a “bottleneck” in distribution, its top health official said Saturday.
Health commissioner Stella Kyriakides told German news agency DPA that any delay in getting approved vaccines out was down to production capacity shortage, not EU planning.
“The bottleneck at the moment is not the volume of orders but the worldwide shortage of production capacity,” she said, in comments distributed by her office.
Kyriakides noted that Brussels had provided 100 million euros to German firm BioNTech, which developed a vaccine with US giant Pfizer, to help build production capacity.
And she said that the bloc was ready to do more, for Pfizer-BioNTech and other companies with candidate vaccines, as the vaccination campaign gets into gear.
“The situation will improve step by step,” she promised, one week after vaccinations began at widely varying paces among EU member states.
“We have been negotiating for additional vaccine doses from BioNTech for a long time and are again ready to help expand production capacities.
“Other manufacturers with whom we have contracts are on the verge of having their vaccines approved by the EU.”
The European Medicines Agency, which advises the European Commission, approved the Pfizer-BioNTech vaccine on December 21.
But it is not expected to rule on a potential alternative from US company Moderna until January 6.
And it is awaiting more data on a candidate from AstraZeneca and Oxford University, which has already been approved in the UK.
But Kyriakides insisted that Europe is not falling behind in its joint procurement programme, backed by the 27 member states.
“If all vaccine candidates are approved, Europe will have more than two billion doses of vaccine available for all 450 million Europeans and their neighbours,” she said.
“And that’s what it’s all about: Europe can get out of this crisis fastest together.”
© 2021 AFP
EU ready to help expand vaccine production (2021, January 2)
retrieved 3 January 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.